Biological therapy of salivary duct carcinoma

Journal of Laryngology and Otology

Volumn 123, Issue 2, 2009, Pages 250-252

  Nashed, M ^a   Casasola, R J ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Carcinoma; Docetaxel; Her 2; Salivary Duct; Trastuzumab

Indexed keywords

DOCETAXEL; DOXORUBICIN; ELECTROLYTE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ADULT; ANAMNESIS; ARTICLE; ASPIRATION BIOPSY; BIOLOGICAL THERAPY; BLOOD CELL COUNT; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; ELECTROLYTE BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LIVER METASTASIS; LUNG METASTASIS; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NECK DISSECTION; NECK METASTASIS; PAROTID GLAND; PAROTIDECTOMY; RADIATION DOSE; SALIVARY GLAND CARCINOMA; TREATMENT RESPONSE; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; METASTASIS; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; PAROTID GLAND TUMOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, DUCTAL; COMBINED MODALITY THERAPY; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PAROTID NEOPLASMS; TAXOIDS; TREATMENT OUTCOME;

EID: 65249155360     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215108002314     Document Type: Article

References (13)

1. Jaehne M, Roeser K, Jaekel T, Schepers JD, Albert N, Loning T. Clinical and immunohistologic typing of salivary duct carcinoma: a report of 50 cases. Cancer 2005;103:2526-33
2. De Potter CR. The neu-oncogene: more than a prognostic indicator? Hum Pathol 1994;25:1264-8
3. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM,Tripathy D et al. Phase II study of receptor-enhanced che- mosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin inpatients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71
4. Skalova A, Starek I, Vanecek T, Kucerova V, Plank L, Szepe P et al. Expression of HER-2/neu gene and proteinin salivary duct carcinomas of parotid gland as revealed by fluorescence in-situ hybridization and immunohisto-chemistry. Histopathology 2003;42:348-56
5. Dagrada GP, Negri T, Tamborini E, Pierotti MA, Pilotti S. Expression of HER-2/neu gene and protein in salivary duct carcinomas of parotid gland as revealed by fluorescencein-situ hybridization and immunohistochemistry. Histo- pathology 2004;44:301-2
6. Hellquist HB, Karlsson MG, Nilsson C. Salivary duct carcinoma - a highly aggressive salivary gland tumour with overexpression of c-erbB-2. J Pathol 1994;172:35-44
7. Etges A, Pinto DS Jr, Kowalski LP, Soares FA, Araujo VC.Salivary duct carcinoma: immunohistochemical profile of an aggressive salivary gland tumour. J Clin Pathol 2003;56:914-18
8. Skalova A, Starek I, Kucerova V, Szepe P, Plank L. Salivary duct carcinoma - a highly aggressive salivary gland tumor with HER-2/neu oncoprotein overexpression.Pathol Res Pract 2001;197:621-6
9. Barnes L, Rao U, Contis L, Krause J, Schwartz A, Scala-mogna P. Salivary duct carcinoma. Part II. Immunohisto chemical evaluation of 13 cases for estrogen and progesterone receptors, cathepsin D, and c-erbB-2 protein. Oral Surg Oral Med Oral Pathol 1994;78:74-80
10. Felix A, El-Naggar AK, Press MF, Ordonez NG, Fonseca I,Tucker SL et al. Prognostic significance of biomarkers(c-erbB-2, p53, proliferating cell nuclear antigen, and DNA content) in salivary duct carcinoma. Hum Pathol 1996;27:561-6
11. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L,Tubiana-Hulin M et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005;23:4265-74
12. Pegram MD, Konecny GE, O'Callaghan C, Beryt M,Pietras R, Slamon DJ. Rational combinations of trastuzu- mab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst2004;96:739-49
13. Sato N, Sano M, Tabei T, Asaga T, Ando J, Fujii H et al.Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study. Breast Cancer 2006;13:166-71